Wasoff Evan L 4
4 · NEXIEN BIOPHARMA, INC. · Filed Oct 30, 2018
Insider Transaction Report
Form 4
Wasoff Evan L
Chief Financial Officer
Transactions
- Award
Stock option - right to buy
2018-10-26+200,000→ 200,000 totalExercise: $0.66From: 2018-10-26Exp: 2025-10-26→ Common Stock (200,000 underlying)
Holdings
- 1,000,000
Common Stock
- 420,000
Stock option - right to buy
Exercise: $0.54From: 2018-07-25Exp: 2025-07-25→ Common Stock (420,000 underlying)
Footnotes (2)
- [F1]Granted under the Company's 2018 Equity Incentive Plan.
- [F2]35,000 options vested immediately, with the remainder vesting monthly over the next 11 months beginning August 1, 2018.